Press release

Go back

Reimbursement for the LiMAx® test - MEL Commission includes LiMAx® test in the MEL list 2022

"The inclusion on the MEL list confirms our assessment of the LiMAx® test in terms of the validity of our clinical data and its relevance for healthcare. This will now result in our unique diagnostic method, which measures the functional capacity of the liver in real time, not only helping patients and physicians alike, but also generating significant economic benefits for the healthcare system in Austria," assesses Ralf Kohnen, CBO of Humedics GmbH.

Liver disease leads to approximately two million deaths per year worldwide. Current diagnostic tools often prove to be of limited applicability for the accurate measurement of liver function or for the prediction of various liver-related pathologies. A novel way of determining global liver function is the LiMAx® (maximum liver function capacity) test, which measures, in exhaled breath, the effectiveness of the liver to metabolize an intravenously administered solution (13C-methacetin).

For numerous diseases, such as malignant liver tumors, the resection of segments of the liver is necessary. In surgical management, the use of the LiMAx® system leads to safer procedures and a reduction in postoperative intensive care unit days as well as days in hospital.

The LiMAx® test is the first and only breath test in liver diagnostics to be included in the MEL list. In addition to convincing clinical data, the economic cost-benefit analysis has confirmed the cost-effectiveness of the LiMAx® system for use in surgery management and this led to its reimbursement.

For further information about Humedics and the LiMAx Test please visit www.humedics.eu

PR-433-00 Press Release Reimbursement AT_English.pdf (119.2 KiB)

Go back

About Humedics

Based in Berlin, Germany, Humedics GmbH is specialised in rapid and accurate liver function measurement using the LiMAx® test, an innovative technology for analysing exhaled air. The LiMAx® test provides physicians with a method for quantitatively assessing an individual patient’s liver function capacity within minutes. This enables physicians to select treatment strategies and follow disease progression based on up-to-date knowledge of the functional health of the liver.
 
Current applications, which have already been published in prestigious medical journals, include liver function diagnosis before and after liver transplantation, surgical planning for liver surgery (such as assessing how much liver tissue can be removed without increasing the risk of acute liver failure), and assessment of liver diseases such as fibrosis and cirrhosis.
 
At present, more than 20 studies regarding new diagnostic indications are being conducted. These include diagnosing and staging of chronic liver diseases such as non-alcoholic steatohepatitis (NASH), as well as selecting, monitoring and managing different oncology treatment options. These studies, initiated by researchers, have already provided evidence of further potential for the LiMAx® tests.
 
The LiMAx® test is in routine clinical use at more than 30 leading university hospitals in Europe. So far, more than 20,000 LiMAx® tests have been performed. The LiMAx® test is commercially available in Germany, Austria and the UK.
 
 

Contact

Humedics GmbH
Bundesallee 23
10717 Berlin
Germany

Phone: +49 30 6293 955 0
info@limaxtest.com
www.limaxtest.com

Go back